EVOTEC SE INH O.N.
Commented by Stefan Feulner on November 21st, 2022 | 11:07 CET
Morphosys, Defence Therapeutics, Evotec - Stabilization after the sell-off
After the publication of the figures for the third quarter, many biotech companies were able to surprise positively. Due to the partly panic-like sell-off in this capital-intensive sector, there are attractive entry opportunities at a strongly discounted level, which should pay off with disproportionate price gains in the long term. The fact that promising companies are already trading below their cash levels shows that the panic is exaggerated. There are currently signs of a bottoming out, which could herald the next upward wave.
Read
Commented by Stefan Feulner on October 26th, 2022 | 11:28 CEST
Biogen, Cardiol Therapeutics, Evotec - Brilliant results
The reporting season for the third quarter is in full swing and is creating a thoroughly positive mood. For example, the software group SAP posted surprisingly strong growth in its cloud business in the third quarter, and its operating result was better than forecast. Positive signals are also coming from the biotech sector, which has been badly battered in recent months. After the horrendous share price losses, this sector, in particular, offers attractive long-term entry levels.
Read
Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST
Evotec, Defence Therapeutics, Formycon - Biotech opportunity!
Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.
Read
Commented by Stefan Feulner on June 16th, 2022 | 11:01 CEST
Biotech stocks ahead of the turnaround - Evotec, NervGen and MorphoSys
Biotechnology stocks could not escape the current correction. The broad-based NASDAQ Biotechnology Index, for example, has lost around 40% since its peak last August. The fact that biotechnology will increasingly become a key technology in the future was already demonstrated during the Corona pandemic when tests, vaccines and drugs were developed in a very short time and made available in large quantities. Thus, more and more capital is likely to move into the sector in the coming years, with great opportunities for the individual companies.
Read
Commented by Stefan Feulner on June 1st, 2022 | 14:03 CEST
After the slump in biotech stocks - Bavarian Nordic, XPhyto and Evotec under review
Biotechnology experienced a boom in March 2020, when the world realized what biotech innovations could do to fight COVID-19. Investors pounced on the many promising technologies, driving up the stock prices of vaccine producers and making it easier for companies to raise capital for financing. However, since September of last year, the biotech sector has been on a steep downhill slide, at least on the stock market. The NASDAQ Biotechnology Index has lost more than 30% of its value since its high of 5,449.26 points until today. This drastic decline is reminiscent of the bursting of the bubble in the year 2000. But where are the opportunities now, and which stocks should investors rather refrain from investing in?
Read
Commented by Carsten Mainitz on January 20th, 2022 | 12:14 CET
Evotec, Defence Therapeutics, Formycon - Who will benefit from Omicron?
The Coronavirus has shown that without biotechnology and ongoing research, we are relatively defenseless against the whims of nature. What would have happened if novel technology had not been available to produce potent vaccines in a very short time? Would our intensive care units have been as crowded as they were in Italy at the beginning of the pandemic? Would hospital triage be the norm today? No one can say for sure, but history has shown how epidemics - such as the Spanish flu - have claimed many lives in the past.
Read
Commented by Carsten Mainitz on August 16th, 2021 | 11:20 CEST
Defence Therapeutics, Moderna, Evotec - Bet on the front-runners!
Health is our most important asset. Biotech companies that protect it save not only human lives but also reap high profits. The price development of many biotech stocks over the past few months has been breathtaking. Investors are advised to focus on the frontrunners, as the market position gained as a first mover, the leadership position in a niche or innovative solution, will enable the companies to keep their competitors at bay for a long time to come.
Read
Commented by Stefan Feulner on August 12th, 2021 | 13:42 CEST
ThyssenKrupp, Triumph Gold, Evotec - Growth before inflation
After the disastrous Corona year 2020 filled with profit slumps, the economy is coming back to life. The quarterly figures currently being reported indicate rising returns once again and thus an end to the dry spell. However, the inflation rate is also rising enormously; in Germany, it jumped to its highest level in almost 30 years, according to the Federal Statistical Office. Growth and job creation take precedence over price stability - a dangerous undertaking for the future. The central banks are being challenged.
Read
Commented by Stefan Feulner on August 4th, 2021 | 12:21 CEST
Evotec, Barsele Minerals, Nikola - When will the starting signal follow?
It has become quiet on the gold market. After the emerging fears of possible interest rate hikes due to rising inflation, the precious yellow metal remains in the range of around USD 1,800 per ounce. The price should be significantly higher due to the continued ultra-loose monetary policy of the central banks and the highs in government debt. Given that a slowdown in bond purchases or even larger interest rate hikes is hardly possible, a rise in the gold price can barely be avoided in the long term. The opportunity for an anticyclical entry is still given.
Read
Commented by Stefan Feulner on May 13th, 2021 | 08:55 CEST
Evotec, RYU Apparel, Adidas - This is just the beginning
Earnings season is in full swing. Yesterday, Bayer, Commerzbank and Varta, among others, presented good figures. Despite Corona restrictions and problems in the supply chain, sporting goods manufacturers were also able to deliver significant jumps in sales. Puma increased its sales by 26% in the first quarter. Along with the home office, sports at home or outdoors is the new trend. And this trend is likely to stay even after the pandemic. The potential for the sporting goods industry is enormous.
Read